Stock PONOU PONO CAPI
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights PONO CAPI Nasdaq

Equities

PONOU

US7324502001

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Japan startup selling $550,000 Star Wars-inspired hoverbike to list on NASDAQ
RE
AERWINS Technologies Inc. completed the acquisition of Pono Capital Corp. from Mehana Equity LLC and others in a reverse merger transaction.
CI
PONO CAPITAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Pono Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
AERWINS Technologies Inc. signed a definitive Agreement and plan of merger to acquire Pono Capital Corp. from Mehana Equity LLC and others for $610 million in a reverse merger transaction.
CI
PONO CAPITAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Pono Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Pono Capital Nixes SPAC Merger Deal With Drug Developer Benuvia
MT
Pono Capital : Announces Termination of Merger Agreement with Benuvia, Inc - Form 8-K
PU
Pono Capital Corp Announces Termination of Merger Agreement with Benuvia, Inc.
AQ
Benuvia Therapeutics Inc. cancelled the acquisition of Pono Capital Corp. from Mehana Equity LLC and others in a reverse merger transaction.
CI
PONO CAPITAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Pono Capital Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Pono Capital Corp. Reports Earnings Results for the Eleven Months Ended December 31, 2021
CI
Cannabinoid Drugmaker Benuvia to Go Public Via SPAC Merger With Pono Capital
MT
Pono Capital : Benuvia, a Leading Drug Developer Focused on Pharmaceutical Cannabinoids, with the FDA Approved Drug SYNDROS®, Signs Definitive Agreement to Become a Publicly Traded Company through a - Form 8-K
PU
Benuvia Therapeutics Inc. entered into an agreement to acquire Pono Capital Corp. from Mehana Equity LLC and others for approximately $400 million in a reverse merger transaction.
CI
Pono Capital Corp. has completed an IPO in the amount of $100 million.
CI
Pono Capital Corp. has filed an IPO in the amount of $100 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PONO Stock
  4. PONOU Stock
  5. News PONO CAPI
  6. Highlights